Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Cingulate Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences
Details : The agreement aims for the manufacturing of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).
Product Name : CTx-1301
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Cingulate Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership